FEB 20, 2017 10:31 AM PST

New Precious Metal Attacks Cancer Where it Counts

WRITTEN BY: Xuan Pham

Researchers have captured how a new organo-metal compound infiltrates cancer cells and destroys its most vulnerable organelle: the mitochondria.

The organo-metal compound, called FY26, is a rare precious metal known as osmium. It was discovered by scientists at the University of Warwick, who previously reported that the metal seemed to shift the metabolism in ovarian cancer cells. In particular, the metal compound stresses cancer cells to use their defective mitochondria, which is a death sentence for these cells.

"Healthy cells generate their energy in organelles called mitochondria, but cancer cells have defective mitochondria and are forced to generate energy through glycolysis in the cytoplasm. Our new compounds work by attacking the energy balance in cancer cells,” explained Dr. Peter Sadler, a professor a the University of Warwick, and the study’s senior author.

In their latest study, Sadler’s team was able to capture just how FY26 targets cancer cells from the inside. They used X-ray fluorescence to track the compound directly to the mitochondria of cancer cells.

"The advanced nano-focussed x-ray beam at ESRF has not only allowed us to locate the site of action of our novel Organo-Osmium FY26 candidate drug in cancer cells at unprecedented resolution, but also study the movement of natural metals such as zinc and calcium in cells. Such studies open up totally new approaches to drug discovery and treatment,” Dr. Sadler said.

In particular, FY26 is reportedly 49 times more potent than Cisplatin - a common platinum-based chemotherapeutic agent.  "Existing platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin,” said Sadler.

The team also argue that, in addition to the higher potency and selectivity, osmium-based drugs may be cheaper to produce overall. "Cancer drugs with new mechanisms of actions which can combat resistance and have fewer side-effects are urgently needed,” Sadler noted.

Of note, the compound was only tested in ovarian cancer cells and with much higher doses than would be typically used in a clinical setting. As such, further investigations into how FY26 behaves in live animal systems are important to determine if this drug will be appropriate for cancer patients.

Additional sources: MNT

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 05, 2020
Cancer
JAN 05, 2020
What does obesity have to do with skin cancer?
You might not think that obesity has anything at all to do with skin cancer. Yes, obesity has been linked as a clear risk factor to other cancers, but&hell...
JAN 11, 2020
Genetics & Genomics
JAN 11, 2020
Single Cells Carry 'Forests' of Chromatin
Researchers are learning more about how every human cell organizes and packages about two meters of DNA....
JAN 16, 2020
Cancer
JAN 16, 2020
FLASH proton therapy: faster and more effective
A new technique called FLASH proposes a new type of radiation therapy. The technique is composed of an ultra-high dose rate of radiotherapy and uses electr...
FEB 11, 2020
Cancer
FEB 11, 2020
Could we be over-diagnosing cancer?
Roughly one in every two people are estimated to receive a cancer diagnosis at some point in their lives, but are all of those diagnoses valid? New researc...
FEB 19, 2020
Clinical & Molecular DX
FEB 19, 2020
Forget complicated scans - ovarian cancer can be detected in the blood
Results from clinical trials performed in Melbourne, Australia have revealed the diagnostic potential of a new test for ovarian cancer. Instead of using co...
FEB 24, 2020
Health & Medicine
FEB 24, 2020
Breast Cancer Screening, without the Radiation
Researchers from the University of Waterloo have developed a prototype of a novel technology that is capable of screening for breast cancer without using r...
Loading Comments...